Tyra Biosciences, Inc.
TYRA
$10.04
-$0.05-0.50%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 7.56M | 5.91M | 5.54M | 5.12M | 4.96M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 29.74M | 28.60M | 23.53M | 22.32M | 25.63M |
Operating Income | -29.74M | -28.60M | -23.53M | -22.32M | -25.63M |
Income Before Tax | -25.57M | -24.02M | -18.70M | -18.19M | -22.83M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -25.57M | -24.02M | -18.70M | -18.19M | -22.83M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -25.57M | -24.02M | -18.70M | -18.19M | -22.83M |
EBIT | -29.74M | -28.60M | -23.53M | -22.32M | -25.63M |
EBITDA | -29.60M | -28.48M | -23.41M | -22.20M | -25.53M |
EPS Basic | -0.43 | -0.41 | -0.32 | -0.35 | -0.53 |
Normalized Basic EPS | -0.27 | -0.25 | -0.20 | -0.22 | -0.33 |
EPS Diluted | -0.43 | -0.41 | -0.32 | -0.35 | -0.53 |
Normalized Diluted EPS | -0.27 | -0.25 | -0.20 | -0.22 | -0.33 |
Average Basic Shares Outstanding | 59.06M | 58.87M | 58.67M | 52.23M | 42.97M |
Average Diluted Shares Outstanding | 59.06M | 58.87M | 58.67M | 52.23M | 42.97M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |